Climb Bio (CLYM) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $9.82, -9.99% vs the prior close of $10.91.
- Volume 990.34K shares, 0.7x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
CLYM slides 10.0% to $9.82, a 3-month low. Closed at $9.82, -9.99% vs the prior close of $10.91. Day range $9.69–$10.89, opened at $10.87.
CLYM daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — CLYM slides 10.0% to $9.82, a 3-month low
- Closed at $9.82, -9.99% vs the prior close of $10.91. Day range $9.69–$10.89, opened at $10.87.
- Volume was 990.34K shares, 0.7x its 50-day average of 1.44M.
- Price is -28.3% vs its 50-day average ($13.70) and -2.6% vs its 200-day average ($10.08).
- 52-week range $1.63–$18.33; today's close sits at 49% of that range, 46.4% below the 52-week high.
Oct 15, 2026 — CLYM jumps 6.0% to $10.91
- Closed at $10.91, +6.03% vs the prior close of $10.29. Day range $10.25–$10.98, opened at $10.32.
- Volume was 515.50K shares, 0.4x its 50-day average of 1.45M — lighter than usual.
- Price is -20.8% vs its 50-day average ($13.78) and +8.5% vs its 200-day average ($10.05).
- 52-week range $1.63–$18.33; today's close sits at 56% of that range, 40.5% below the 52-week high.
Oct 14, 2026 — CLYM ends flat (-0.2%) to $10.29, a 3-month low, 3 down days in a row
- Closed at $10.29, -0.19% vs the prior close of $10.31. Day range $10.09–$10.64, opened at $10.19.
- Volume was 987.70K shares, 0.7x its 50-day average of 1.45M.
- Price is -25.5% vs its 50-day average ($13.81) and +2.7% vs its 200-day average ($10.02).
- 52-week range $1.63–$18.33; today's close sits at 52% of that range, 43.9% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — CLYM slides 4.8% to $10.31, a 3-month low
- Closed at $10.31, -4.80% vs the prior close of $10.83. Day range $10.18–$10.79, opened at $10.75.
- Volume was 901.30K shares, 0.6x its 50-day average of 1.45M.
- Price is -25.6% vs its 50-day average ($13.86) and +3.2% vs its 200-day average ($9.99).
- 52-week range $1.63–$18.33; today's close sits at 52% of that range, 43.8% below the 52-week high.
Oct 12, 2026 — CLYM dips 1.5% to $10.83
- Closed at $10.83, -1.55% vs the prior close of $11.00. Day range $10.73–$11.15, opened at $10.91.
- Volume was 911.60K shares, 0.6x its 50-day average of 1.45M.
- Price is -22.0% vs its 50-day average ($13.89) and +8.7% vs its 200-day average ($9.97).
- 52-week range $1.63–$18.33; today's close sits at 55% of that range, 40.9% below the 52-week high.
Oct 9, 2026 — CLYM rises 1.3% to $11.00, 3 up days in a row
- Closed at $11.00, +1.29% vs the prior close of $10.86. Day range $10.75–$11.30, opened at $10.81.
- Volume was 638.00K shares, 0.4x its 50-day average of 1.47M — lighter than usual.
- Price is -20.9% vs its 50-day average ($13.91) and +10.7% vs its 200-day average ($9.94).
- 52-week range $1.63–$18.33; today's close sits at 56% of that range, 40.0% below the 52-week high.
- That makes 3 straight gains.
Oct 8, 2026 — CLYM rises 1.4% to $10.86
- Closed at $10.86, +1.40% vs the prior close of $10.71. Day range $10.27–$11.00, opened at $10.55.
- Volume was 1.15M shares, 0.8x its 50-day average of 1.46M.
- Price is -22.0% vs its 50-day average ($13.93) and +9.6% vs its 200-day average ($9.91).
- 52-week range $1.63–$18.33; today's close sits at 55% of that range, 40.8% below the 52-week high.
Oct 7, 2026 — CLYM ends flat (+0.3%) to $10.71
- Closed at $10.71, +0.28% vs the prior close of $10.68. Day range $10.34–$10.94, opened at $10.43.
- Volume was 755.80K shares, 0.5x its 50-day average of 1.47M — lighter than usual.
- Price is -23.3% vs its 50-day average ($13.96) and +8.5% vs its 200-day average ($9.87).
- 52-week range $1.54–$18.33; today's close sits at 55% of that range, 41.6% below the 52-week high.
Oct 6, 2026 — CLYM slides 3.3% to $10.68, a 3-month low
- Closed at $10.68, -3.35% vs the prior close of $11.05. Day range $10.64–$11.25, opened at $11.12.
- Volume was 953.60K shares, 0.6x its 50-day average of 1.47M.
- Price is -23.6% vs its 50-day average ($13.99) and +8.5% vs its 200-day average ($9.84).
- 52-week range $1.54–$18.33; today's close sits at 54% of that range, 41.7% below the 52-week high.
Oct 5, 2026 — CLYM rises 1.0% to $11.05
- Closed at $11.05, +1.01% vs the prior close of $10.94. Day range $10.70–$11.20, opened at $10.94.
- Volume was 1.21M shares, 0.8x its 50-day average of 1.46M.
- Price is -21.2% vs its 50-day average ($14.03) and +12.7% vs its 200-day average ($9.81).
- 52-week range $1.54–$18.33; today's close sits at 57% of that range, 39.7% below the 52-week high.
Oct 2, 2026 — CLYM dips 1.2% to $10.94, a 3-month low, 4 down days in a row
- Closed at $10.94, -1.17% vs the prior close of $11.07. Day range $10.73–$11.29, opened at $11.29.
- Volume was 1.57M shares, 1.1x its 50-day average of 1.44M.
- Price is -22.2% vs its 50-day average ($14.07) and +11.9% vs its 200-day average ($9.78).
- 52-week range $1.54–$18.33; today's close sits at 56% of that range, 40.3% below the 52-week high.
- That makes 4 straight losses.
CLYM latest news & SEC filings
Every SEC filing by or about CLYM in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 30, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Ra Capital Management, L.P. & Ra Capital Healthcare Fund Lp & Ra Capital Nexus Fund, L.P. & Ra Capital Nexus Fund Ii, L.P. & Ra Capital Nexus Fund Iii, L.P. & Kolchinsky Peter & Shah Rajeev M. converted options/RSUs into 10,000 shares at $3.46 (≈$34.60K) on Sep 28, 2026; now holds 10,000
- Ra Capital Management, L.P. & Ra Capital Healthcare Fund Lp & Ra Capital Nexus Fund, L.P. & Ra Capital Nexus Fund Ii, L.P. & Ra Capital Nexus Fund Iii, L.P. & Kolchinsky Peter & Shah Rajeev M. converted options/RSUs into 10,000 shares at $3.00 (≈$30.00K) on Sep 28, 2026; now holds 20,000
- Ra Capital Management, L.P. & Ra Capital Healthcare Fund Lp & Ra Capital Nexus Fund, L.P. & Ra Capital Nexus Fund Ii, L.P. & Ra Capital Nexus Fund Iii, L.P. & Kolchinsky Peter & Shah Rajeev M. converted options/RSUs into 10,000 shares at $7.89 (≈$78.90K) on Sep 28, 2026; now holds 30,000
- Ra Capital Management, L.P. & Ra Capital Healthcare Fund Lp & Ra Capital Nexus Fund, L.P. & Ra Capital Nexus Fund Ii, L.P. & Ra Capital Nexus Fund Iii, L.P. & Kolchinsky Peter & Shah Rajeev M. converted options/RSUs into 40,000 shares at $1.29 (≈$51.60K) on Sep 28, 2026; now holds 70,000
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Thomas Stephen Basil sold 100,000 shares at $13.67 (≈$1.37M) on Sep 15, 2026; now holds 467,969
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 15, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 3, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$13.50M (prior year -$8.67M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.18 (prior year -$0.13) (loss widened vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 8, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 7, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 1, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 1, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 1, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Jul 1, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Things to know before you trade CLYM
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Mar 5, 2026, Nov 6, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.17% (largest 11.9%). That is a volatile stock.
- Liquidity: about 1.13M shares (≈$11.10M) trade per day on average.
- 52-week position: $9.82 vs a range of $1.63–$18.33 (49% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 1 open-market buys, 24 sales; latest: Stephen Basil Thomas sold 100,000 shares on Sep 15, 2026.
- Latest filings: 8-K Sep 3, 2026; 8-K Aug 14, 2026; 10-Q Aug 6, 2026.
- Share count: 57.44M shares outstanding (Jul 31, 2026), -15.2% vs a year earlier — the company has been reducing its share count.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
CLYM market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 10.87 | 10.89 | 9.69 | 9.82 | 990.34K |
| Oct 15, 2026 | 10.32 | 10.98 | 10.25 | 10.91 | 515.50K |
| Oct 14, 2026 | 10.19 | 10.64 | 10.09 | 10.29 | 987.70K |
| Oct 13, 2026 | 10.75 | 10.79 | 10.18 | 10.31 | 901.30K |
| Oct 12, 2026 | 10.91 | 11.15 | 10.73 | 10.83 | 911.60K |
| Oct 9, 2026 | 10.81 | 11.30 | 10.75 | 11.00 | 638.00K |
| Oct 8, 2026 | 10.55 | 11.00 | 10.27 | 10.86 | 1.15M |
| Oct 7, 2026 | 10.43 | 10.94 | 10.34 | 10.71 | 755.80K |
| Oct 6, 2026 | 11.12 | 11.25 | 10.64 | 10.68 | 953.60K |
| Oct 5, 2026 | 10.94 | 11.20 | 10.70 | 11.05 | 1.21M |
| Oct 2, 2026 | 11.29 | 11.29 | 10.73 | 10.94 | 1.57M |
| Oct 1, 2026 | 11.39 | 11.67 | 11.03 | 11.07 | 953.00K |
| Sep 30, 2026 | 11.69 | 11.93 | 11.32 | 11.47 | 1.41M |
| Sep 29, 2026 | 11.79 | 11.81 | 11.31 | 11.50 | 1.14M |
| Sep 28, 2026 | 11.57 | 11.93 | 11.39 | 11.74 | 811.00K |
| Sep 25, 2026 | 11.89 | 11.92 | 11.53 | 11.66 | 1.53M |
| Sep 24, 2026 | 12.35 | 12.42 | 11.38 | 11.89 | 1.87M |
| Sep 23, 2026 | 14.29 | 14.39 | 12.06 | 12.52 | 2.14M |
| Sep 22, 2026 | 13.75 | 14.29 | 13.63 | 14.21 | 930.00K |
| Sep 21, 2026 | 14.13 | 14.23 | 13.55 | 13.64 | 1.22M |
About Climb Bio
Climb Bio (CLYM) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in WELLESLEY HILLS, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1768446.
CLYM board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Aoife Brennan | President and CEO | Jun 30, 2026 |
| Breanna Maurine Celebi | Director | Jul 1, 2026 |
| Alexander Cumbo | Director | Jun 8, 2026 |
| Kimberlee C Drapkin | Director | Jun 8, 2026 |
| Judith Dunn | Director | Jun 8, 2026 |
| Peter Kolchinsky | Director | Sep 30, 2026 |
| Andrew David Levin | Director | Jun 8, 2026 |
| Capital Management, L.P. Ra | Director | Sep 30, 2026 |
| Capital Healthcare Fund Lp Ra | Director | Sep 30, 2026 |
| Capital Nexus Fund Ii, L.P. Ra | Director | Sep 30, 2026 |
| Capital Nexus Fund Iii, L.P. Ra | Director | Sep 30, 2026 |
| Capital Nexus Fund, L.P. Ra | Director | Sep 30, 2026 |
| Rajeev M. Shah | Director | Sep 30, 2026 |
| Stephen Basil Thomas | Director | Sep 17, 2026 |
| Douglas E Williams | Director | Jun 8, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Susan Altschuller | Chief Financial Officer | Jan 8, 2026 |
| Aoife Brennan | President and CEO | Jun 30, 2026 |
| Cindy Driscoll | Senior Vice President, Finance | Jan 8, 2026 |
| Perrin Megan Wilson | Chief Business Officer | Jan 8, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 15, 2026 | Stephen Basil Thomas | Sale | 100,000 | $13.67 |
| Sep 15, 2026 | Stephen Basil Thomas | Sale | 100,000 | $13.67 |
| Sep 15, 2026 | Stephen Basil Thomas | Sale | 100,000 | $13.67 |
| Sep 15, 2026 | Stephen Basil Thomas | Sale | 100,000 | $13.67 |
| Jun 29, 2026 | Aoife Brennan | Sale | 30,902 | $13.17 |
| Jun 29, 2026 | Aoife Brennan | Sale | 30,902 | $13.17 |
| Jun 29, 2026 | Aoife Brennan | Sale | 30,902 | $13.17 |
| Jun 29, 2026 | Aoife Brennan | Sale | 30,902 | $13.17 |
| Feb 26, 2026 | Stephen Basil Thomas | Sale | 16,313 | $7.01 |
| Feb 26, 2026 | Stephen Basil Thomas | Sale | 16,313 | $7.01 |
| Feb 26, 2026 | Stephen Basil Thomas | Sale | 16,313 | $7.01 |
| Feb 26, 2026 | Stephen Basil Thomas | Sale | 16,313 | $7.01 |
| Feb 25, 2026 | Stephen Basil Thomas | Sale | 33,687 | $7.00 |
| Feb 25, 2026 | Stephen Basil Thomas | Sale | 33,687 | $7.00 |
| Feb 25, 2026 | Stephen Basil Thomas | Sale | 33,687 | $7.00 |
CLYM financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-59.85M | -0.88 | $-54.36M |
| Dec 31, 2024 | — | $-73.90M | -1.53 | $-15.56M |
| Dec 31, 2023 | — | $-35.12M | -1.30 | $-20.60M |
| Dec 31, 2022 | — | $-45.24M | -1.72 | $-37.37M |
| Dec 31, 2021 | — | $-47.48M | -4.24 | $-36.07M |
Latest balance sheet: total assets $246.29M, total liabilities $6.75M, cash $44.11M (as of Jun 30, 2026).
CLYM earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $14.00 |
| May 7, 2026 | 8-K Item 2.02 (results) | $11.91 |
| Mar 5, 2026 | 8-K Item 2.02 (results) | $7.39 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $1.95 |
| Aug 12, 2025 | 8-K Item 2.02 (results) | $1.61 |
| May 14, 2025 | 8-K Item 2.02 (results) | $1.17 |
| Mar 25, 2025 | 8-K Item 2.02 (results) | $1.30 |
| Jan 10, 2025 | 8-K Item 2.02 (results) | $2.00 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $3.80 |
| Oct 15, 2024 | 8-K Item 2.02 (results) | — |
| Aug 14, 2024 | 8-K Item 2.02 (results) | — |
| Jul 20, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on CLYM
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.